Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) remains the standard of treatment in select patients with peritoneal metastases of colorectal (PMCRC) origin.
1 Given the relatively high morbidity associated with CRS, the selection of patients must be optimal in terms of prognostic benefits.
2 While various histological growth patterns (HGP) are being explored in liver metastases of colorectal cancer (CRC) origin (LMCRC) to help determine the prognosis of patients, peritoneal cancer index (PCI) and the completeness of cytoreduction (CC-0) remain the only parameters when it comes to PMCRC, hence the need for additional prognostic factors in these patients.
3,4 …